MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 89 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,118,378 | -23.8% | 138,929 | +2.9% | 0.00% | – |
| Q2 2023 | $1,466,806 | +986.3% | 135,065 | +590.2% | 0.00% | – |
| Q1 2023 | $135,026 | +37.6% | 19,569 | -20.6% | 0.00% | – |
| Q4 2022 | $98,147 | +14.1% | 24,660 | +92.5% | 0.00% | – |
| Q3 2022 | $86,000 | +38.7% | 12,809 | 0.0% | 0.00% | – |
| Q2 2022 | $62,000 | -93.0% | 12,809 | -86.5% | 0.00% | – |
| Q1 2022 | $889,000 | -19.4% | 95,047 | +2.5% | 0.00% | – |
| Q4 2021 | $1,103,000 | +4.5% | 92,766 | 0.0% | 0.00% | – |
| Q3 2021 | $1,056,000 | -35.4% | 92,766 | +1.9% | 0.00% | -100.0% |
| Q2 2021 | $1,634,000 | +41.0% | 91,045 | +21.7% | 0.00% | – |
| Q1 2021 | $1,159,000 | +54.5% | 74,832 | +21.8% | 0.00% | – |
| Q4 2020 | $750,000 | +1.5% | 61,420 | +6.9% | 0.00% | – |
| Q3 2020 | $739,000 | – | 57,466 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |